Corrigendum re "Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial" [Eur Urol 2019;76:823-30].

Kellokumpu-Lehtinen, Pirkko-Liisa; Hjälm-Eriksson, Marie; Thellenberg-Karlsson, Camilla; Åström, Lennat; Franzen, Lars; Fransson, Ann-Fofie; Leskinen, Markku J; Zeke, Mihalj; Huttunen, Teppo; Ginman, Claes

Kellokumpu-Lehtinen, Pirkko-Liisa; Hjälm-Eriksson, Marie; Thellenberg-Karlsson, Camilla; Åström, Lennat; Franzen, Lars; Fransson, Ann-Fofie; Leskinen, Markku J; Zeke, Mihalj; Huttunen, Teppo; Ginman, Claes.

Afiliação

Kellokumpu-Lehtinen PL; Tampere University Hospital, Tampere, Finland. Electronic address: pirkko-liisa.kellokumpu-lehtinen@tuni.fi.
Hjälm-Eriksson M; Department of Surgery, Capio S.T. Görans Hospital, Stockholm, Sweden; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Thellenberg-Karlsson C; Department of Radiation Sciences, Oncology, Umeå University Hospital, Umeå, Sweden.
Åström L; Uppsala University Hospital, Uppsala, Sweden.
Franzen L; Sundsvall University Hospital, Sundsvall, Sweden.
Fransson AF; Gävle Central Hospital, Gävle, Sweden.
Leskinen MJ; Seinäjoki Central Hospital, Seinäjoki, Finland.
Zeke M; Växjö Central Hospital, Växjö, Sweden.
Huttunen T; 4Pharma, Turku, Finland.
Ginman C; Karlstad Central Hospital, Karlstad, Sweden.

Eur Urol ; 78(6): e241-e242, 2020 Dec.

Article em En | MEDLINE | ID: mdl-32893063

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies / Screening_studies Idioma: En Revista: Eur Urol Ano de publicação: 2020 Tipo de documento: Article País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google